Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Lynch

Showing results (1-10 of 251) with videos related to

Pageof 26
Sort By:
The Lancet. Neurology|November 15, 2016
Challenges ahead for trials in Friedreich's ataxiaDavid R Lynch, Elizabeth Kichula
Annals of Neurology|August 28, 2014
Friedreich ataxia: new findings, new challengesDavid R Lynch, Lauren Seyer
Neuronal Signaling|May 28, 2021
Mitochondrial and metabolic dysfunction in Friedreich ataxia: update on pathophysiological relevance and clinical interventionsDavid R Lynch, Garrett Farmer
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society|December 5, 2002
Practical approaches to neurogenetic diseaseDavid R Lynch, Jennifer Farmer
Expert Opinion on Pharmacotherapy|April 15, 2024
Pharmacotherapeutic strategies for Friedreich Ataxia: a review of the available dataKatherine Gunther, David R Lynch
Frontiers in Bioscience (Scholar Edition)|June 2, 2009
Calpain and the glutamatergic synapseShachee Doshi, David R Lynch
Neurodegenerative Disease Management|January 12, 2021
Omaveloxolone: potential new agent for Friedreich ataxiaDavid R Lynch, Joseph Johnson
Pediatric Neurology|January 30, 2002
Juvenile dentatorubral-pallidoluysian atrophy: new clinical featuresDaniel J Licht, David R Lynch
The Journal of Biological Chemistry|June 22, 2005
N-methyl-D-aspartate receptor subtype mediated bidirectional control of p38 mitogen-activated protein kinaseElisa A Waxman, David R Lynch
Expert Opinion on Emerging Drugs|October 25, 2021
Designing phase II clinical trials in Friedreich ataxiaLayne N Rodden, David R Lynch
Pageof 26

Showing results (1-10 of 251) with videos related to

Sort By:
Pageof 26
The Lancet. Neurology|November 15, 2016
Challenges ahead for trials in Friedreich's ataxiaDavid R Lynch, Elizabeth Kichula
Annals of Neurology|August 28, 2014
Friedreich ataxia: new findings, new challengesDavid R Lynch, Lauren Seyer
Neuronal Signaling|May 28, 2021
Mitochondrial and metabolic dysfunction in Friedreich ataxia: update on pathophysiological relevance and clinical interventionsDavid R Lynch, Garrett Farmer
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society|December 5, 2002
Practical approaches to neurogenetic diseaseDavid R Lynch, Jennifer Farmer
Expert Opinion on Pharmacotherapy|April 15, 2024
Pharmacotherapeutic strategies for Friedreich Ataxia: a review of the available dataKatherine Gunther, David R Lynch
Frontiers in Bioscience (Scholar Edition)|June 2, 2009
Calpain and the glutamatergic synapseShachee Doshi, David R Lynch
Neurodegenerative Disease Management|January 12, 2021
Omaveloxolone: potential new agent for Friedreich ataxiaDavid R Lynch, Joseph Johnson
Pediatric Neurology|January 30, 2002
Juvenile dentatorubral-pallidoluysian atrophy: new clinical featuresDaniel J Licht, David R Lynch
The Journal of Biological Chemistry|June 22, 2005
N-methyl-D-aspartate receptor subtype mediated bidirectional control of p38 mitogen-activated protein kinaseElisa A Waxman, David R Lynch
Expert Opinion on Emerging Drugs|October 25, 2021
Designing phase II clinical trials in Friedreich ataxiaLayne N Rodden, David R Lynch
Pageof 26